Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes

被引:20
|
作者
Laugier-Robiolle, Stephanie [1 ,2 ]
Verges, Bruno [3 ]
Le Bras, Maelle [4 ]
Gand, Elise [1 ,2 ]
Bouillet, Benjamin [3 ]
Saulnier, Pierre-Jean [5 ]
Le May, Cedric [6 ]
Pichelin, Matthieu [7 ]
Marechaud, Richard [1 ,2 ]
Petit, Jean-Michel [3 ]
Hadjadj, Samy [1 ,2 ,5 ,8 ]
Cariou, Bertrand [7 ]
机构
[1] CHU Poitiers, Endocrinol Diabetol, Poitiers, France
[2] CHU Poitiers, CIC1402, Poitiers, France
[3] Univ Bourgogne, Dept Endocrinol, INSERM, CRI 866,CHU Dijon, Dijon, France
[4] CHU Nantes, Inst Thorax, Dept Endocrinol, Nantes, France
[5] INSERM, CIC1402, Poitiers, France
[6] Univ Nantes, Inst Thorax, INSERM, CNRS, Nantes, France
[7] Univ Nantes, CHU Nantes, Dept Endocrinol, Inst Thorax,INSERM,CNRS, Nantes, France
[8] Univ Poitiers, UFR Med Pharm, Poitiers, France
来源
DIABETES OBESITY & METABOLISM | 2017年 / 19卷 / 03期
关键词
dyslipidaemia; lipid-lowering therapy; type; 1; diabetes; SUBTILISIN/KEXIN TYPE 9; CARDIOVASCULAR-DISEASE; ASSOCIATION; EXPRESSION; INSULIN;
D O I
10.1111/dom.12819
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of LDL cholesterol metabolism. Little is known, however, about the regulation of PCSK9 in patients with type 1 diabetes (T1D). In the present study, we aimed to determine the relationship between circulating PCSK9 and metabolic variables in T1D. Plasma PCSK9 levels were measured in 195 people with T1D (mean age 38.8 years, mean diabetes duration 17.2 years, mean glycated haemoglobin [HbA1c] 8.3%), who were free of any lipid-lowering agent. Plasma PCSK9 was positively correlated with LDL cholesterol (P =.0007), triglycerides (P =.004), apolipoprotein B (P =.005), HbA1c (P =.003), systolic (P =.003) and diastolic (P =.001) blood pressure and body mass index (0.02). In multivariate analysis, PCSK9 concentration was independently associated with HbA1c (P =.02) and LDL cholesterol (P =.03). After classifying patients according to HbA1c tertile, the correlation between PCSK9 and LDL cholesterol was only observed in the highest tertile (P =.0006; Rho = 0.43), whereas no correlation was found in the lowest and intermediate tertiles. This study suggests that good glycaemic control abolishes the positive relationship between PCSK9 and LDL cholesterol in patients with T1D; however, the underlying molecular mechanisms remain to be established.
引用
收藏
页码:448 / 451
页数:4
相关论文
共 50 条
  • [1] Lack of association between plasma PCSK9 and LDL-cholesterol in patients with controlled type 1 diabetes
    Laugier-Robiolle, S.
    Verges, B.
    Hadjadj, S.
    Cariou, B.
    DIABETOLOGIA, 2015, 58 : S129 - S129
  • [2] PCSK9 antibody reduces LDL cholesterol
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2012, 11 : 11 - 11
  • [3] The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
    Piper, Derek E.
    Jackson, Simon
    Liu, Qiang
    Romanow, William G.
    Shetterly, Susan
    Thibault, Stephen T.
    Shan, Bei
    Walker, Nigel P. C.
    STRUCTURE, 2007, 15 (05) : 545 - 552
  • [4] Inverse relationship between LDL cholesterol and PCSK9 plasma levels in dyslipidemic cynomolgus monkeys: Effects of LDL lowering by ezetimibe in the absence of statins
    Hentze, Hannes
    Jensen, Kristian K.
    Chia, Ser Mien
    Johns, Douglas G.
    Shaw, Rachel J.
    Davis, Harry R., Jr.
    Shih, Shian-Jiun
    Wong, Kenny K.
    ATHEROSCLEROSIS, 2013, 231 (01) : 84 - 90
  • [5] BOTH CIRCADIAN CLOCK AND SLEEP CONTROL PLASMA LEVELS OF PCSK9, THE MAIN REGULATOR OF PLASMA LDL CHOLESTEROL
    Butler, Matthew P.
    Thosar, Saurabh S.
    Tavori, Hagai
    Rueger, Melanie
    Barr, David A.
    Miles, Joshua R.
    Fazio, Sergio S.
    Shea, Steven A.
    SLEEP, 2019, 42
  • [6] Chasing LDL cholesterol to the bottom — PCSK9 in perspective
    Peter Libby
    Lale Tokgözoğlu
    Nature Cardiovascular Research, 2022, 1 : 554 - 561
  • [7] Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    Stein, Evan A.
    Mellis, Scott
    Yancopoulos, George D.
    Stahl, Neil
    Logan, Douglas
    Smith, William B.
    Lisbon, Eleanor
    Gutierrez, Maria
    Webb, Cheryle
    Wu, Richard
    Du, Yunling
    Kranz, Therese
    Gasparino, Evelyn
    Swergold, Gary D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (12): : 1108 - 1118
  • [8] PCSK9 MUTATIONS: EFFECTS BEYOND LDL CHOLESTEROL
    Zampoleri, V.
    Casula, M.
    Gazzotti, M.
    Baragetti, A.
    Pellegatta, F.
    Grigore, L.
    Catapano, A. L.
    ATHEROSCLEROSIS, 2019, 287 : E195 - E196
  • [9] Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    Banerjee, Yajnavalka
    Shah, Karna
    Al-Rasadi, Khalid
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (25): : 2425 - 2426
  • [10] Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
    Tavori, Hagai
    Melone, Michelle
    Rashid, Shirya
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (10) : 1137 - 1144